Ovulation induction in a poor responder with panhypopituitarism: a case report and review of the literature

Gynecol Endocrinol. 2007 Feb;23(2):82-6. doi: 10.1080/09513590601137533.

Abstract

Background: Most women with panhypopituitarism will undergo successful ovulation induction with gonadotropin therapy. Few proven treatment options exist for those who respond poorly to such therapy. A poor response may indicate diminished ovarian reserve, or reflect a deficiency of other key components for ovarian function.

Case: A 31-year-old female with panhypopituitarism and a poor response to gonadotropin therapy took growth hormone (GH) replacement for 4 months prior to restarting gonadotropins. When the serum level of insulin-like growth factor-I normalized, she began ovulation induction with gonadotropins with transdermal estradiol. After 63 days of gonadotropin therapy, she had a leading follicle of 18 mm, followed by follicles of 16.5 mm and 15.5 mm. The serum estradiol was 796 pg/ml, and human chorionic gonadotropin was administered. The patient conceived with timed intercourse. A prior attempt at ovulation induction with gonadotropins alone failed to produce follicular development.

Conclusion: Prolonged gonadotropin treatment may be necessary to achieve ovulation and avoid the misdiagnosis of ovarian failure. Co-treatment with GH and estrogen may improve the follicular response in a poor responder with panhypopituitarism.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Estradiol / therapeutic use*
  • Female
  • Follicle Stimulating Hormone / therapeutic use*
  • Human Growth Hormone / therapeutic use*
  • Humans
  • Hypopituitarism / drug therapy*
  • Insulin-Like Growth Factor I / analysis
  • Insulin-Like Growth Factor I / drug effects
  • Live Birth
  • Menotropins / therapeutic use*
  • Ovarian Follicle / diagnostic imaging
  • Ovulation Induction / methods*
  • Pregnancy
  • Ultrasonography

Substances

  • Human Growth Hormone
  • Estradiol
  • Menotropins
  • Insulin-Like Growth Factor I
  • Follicle Stimulating Hormone